A tiny UK biotech just posted positive Phase 2a data for a lung disease drug that takes the opposite approach to Insmed's billion-dollar Brinsupri. The safety looks clean, the dosing schedule is quarterly, and the efficacy signal is intriguing. Is there room for two players in NCFB?
Imagine you finally get a table at the hottest restaurant in town. You sit down, order the tasting menu, and then some scrappy food truck parks outside and starts handing out samples of a dish that might be better. That's roughly what's happening in non-cystic fibrosis bronchiectasis (NCFB) right now.
Insmed spent years building the only approved treatment for this chronic lung disease. Its oral pill Brinsupri launched last year and is already printing money: $207.9 million in Q1 2026 alone, up 44% from the prior quarter. The company is guiding for at least $1 billion in Brinsupri revenue this year.
And now, a small biotech from the English countryside just pulled up in the food truck.
Meet the Challenger from Alderley Park
Infex Therapeutics is a clinical-stage company based at Alderley Park in Cheshire, England. It was founded in 2016 as AMR Centre Limited, part of the UK's push to fight antimicrobial resistance. It rebranded in 2020, and until recently, it had raised roughly $9 million total across its entire life. For context, Insmed ended 2025 sitting on about $1.4 billion in cash.
This is not exactly a fair fight on paper.
But last week, Infex reported positive Phase 2a results for RESP-X (also called INFEX702), an antibody designed to treat NCFB patients whose lungs are colonized by a nasty bacterium called Pseudomonas aeruginosa. The data, presented as a late-breaking abstract at the ATS 2026 conference, checked enough boxes to move the drug forward into a larger Phase 2b trial.
The question isn't whether Infex can topple Insmed tomorrow. It can't. The question is whether its approach fills a gap that Brinsupri doesn't.
A Completely Different Playbook
To understand why RESP-X matters, you need to understand how differently it works compared to Brinsupri.
Brinsupri is an anti-inflammatory pill. It targets enzymes that drive the destructive inflammation in NCFB lungs. Think of it as turning down the volume on the body's overreaction to infection. It works across the broad NCFB population, regardless of which specific bug is causing trouble.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
RESP-X takes the opposite angle. It's a monoclonal antibody that goes after the bacteria itself, specifically Pseudomonas aeruginosa. But it doesn't kill the bug directly. Instead, it blocks a protein called PcrV, which is part of the bacterium's "injection system" (the Type III Secretion System, or T3SS). Normally, Pseudomonas uses this system like a tiny syringe to pump toxins into human cells, damaging tissue and dodging the immune system.
RESP-X jams the syringe. Without its toxin-delivery weapon, Pseudomonas becomes much less dangerous, and the patient's own immune system can actually fight back. Scientists call this an "anti-virulence" strategy: you don't kill the bacteria, you just strip away its superpowers.
It's like taking the claws off a cat. Still a cat. Just a much less threatening one.
What the Phase 2a Actually Showed
The trial was randomized, double-blind, and placebo-controlled, which is the gold standard for early clinical studies. Patients with NCFB who were colonized with Pseudomonas received one of two IV doses of RESP-X (6 mg/kg or 10 mg/kg) or a placebo. The primary goals were safety, pharmacokinetics (how the drug moves through the body), and lung delivery.
On safety, it was basically spotless. No severe or life-threatening side effects were linked to the drug. No patients dropped out because of adverse events. No infusion reactions. No anti-drug antibodies (which can cause the body to reject a biologic over time). Every reported side effect was mild to moderate.
The pharmacokinetics were encouraging too. RESP-X had a half-life of about 29 days, meaning it sticks around in the body long enough to support quarterly dosing: one infusion every three months. For a chronic disease that requires long-term management, that's a compelling schedule. The drug also showed up in lung tissue (specifically, the epithelial lining fluid) within 48 hours of dosing, confirming it actually gets where it needs to go.
Then there's the efficacy signal, and this is where things get interesting and tricky.
Patients on RESP-X had fewer lung flare-ups over the six-month study compared to their own exacerbation rates in the prior year. That's encouraging, but the p-value came in at 0.08, which is just above the traditional 0.05 cutoff for statistical significance. In plain English: the trend looks real, but the study was too small to say so with full confidence.
For a Phase 2a trial, that's not a disaster. This study was designed to test safety first, not to prove efficacy. The exacerbation data was exploratory. But it gives Infex something to build on in a bigger, properly powered Phase 2b.
The Insmed Comparison Is Inevitable (But Incomplete)
FierceBiotech framed the news as Infex "following in Insmed's footsteps," and it's easy to see why. Both companies are going after NCFB. Both want to reduce exacerbations. Both are building franchises around underserved lung diseases.
But the comparison only goes so far.
Brinsupri is a broad anti-inflammatory for all NCFB patients. RESP-X is a targeted anti-virulence weapon for the subset colonized with Pseudomonas. Think of Brinsupri as a fire extinguisher that works on any fire. RESP-X is a specialized tool designed for one specific type of blaze, but potentially more effective at putting that particular fire out.
This distinction matters clinically. Pseudomonas colonization in NCFB patients is associated with worse outcomes, more frequent exacerbations, and faster lung function decline. These are some of the sickest patients in the NCFB population. If RESP-X can meaningfully reduce their flare-ups, it could complement Brinsupri rather than compete with it directly. Imagine a future where a Pseudomonas-positive NCFB patient takes daily Brinsupri to calm inflammation and gets a quarterly RESP-X infusion to neuter the bacteria.
Of course, that future depends on Phase 2b (and eventually Phase 3) data that haven't been generated yet.
The David-and-Goliath Math
Let's be honest about the scale mismatch. Insmed is guiding for combined revenues of roughly $1.45 to $1.47 billion in 2026 from Brinsupri and its other big product, ARIKAYCE (an inhaled antibiotic for a related lung infection). The company just raised $750 million in equity last year. It has a deep pipeline extending into pulmonary hypertension, chronic rhinosinusitis, and hidradenitis suppurativa.
Infex, meanwhile, just closed a £4.3 million raise (about $5.8 million) in May 2026, led by prominent UK venture capitalist Jon Moulton. That's its war chest for regulatory discussions and Phase 2b planning. The company also has MET-X, an antibiotic resistance program, in its pipeline, but RESP-X is the clear lead asset.
This isn't a weakness so much as a reality check. Infex doesn't need to match Insmed's scale to create value. It needs to generate clean Phase 2b data in its target population. If it does, the company becomes an attractive acquisition target or licensing partner for larger pharma players hunting for differentiated respiratory assets.
Why This Matters Beyond One Small Trial
Zoom out, and the bigger story is about the NCFB market itself. Before Brinsupri's approval in August 2025, there was zero approved disease-specific therapy for bronchiectasis. Patients relied on airway clearance techniques, off-label antibiotics, and a lot of hope.
Inhaled and lung-targeted therapies already account for more than 60% of NTM market revenue, and the broader bronchiectasis space is following a similar trajectory: moving from generic, untargeted approaches to specific, mechanism-driven treatments.
Infex's RESP-X fits neatly into this evolution. It's the kind of precision approach (target a specific pathogen's virulence mechanism in a defined patient subset) that could carve out a meaningful niche even in a market where Insmed is the clear leader.
The Bottom Line
Infex isn't going to threaten Insmed's dominance anytime soon. But that's not the point. The Phase 2a data for RESP-X did exactly what early-stage data is supposed to do: it showed the drug is safe, it gets to the lungs, it lasts long enough for quarterly dosing, and there's a hint that it reduces the lung flare-ups that make life miserable for Pseudomonas-colonized NCFB patients.
Now comes the hard part. A bigger trial, a tougher statistical bar, and a regulatory landscape where Brinsupri has already set expectations for what an NCFB drug should deliver.
But if you're watching the inhaled pulmonary therapy space, put Infex on your radar. The food truck just served its first sample, and the early reviews are good enough to keep the line forming.
5 min read
Lilly Just Paid $202M for a Company With Zero Drugs
Eli Lilly dropped up to $202 million on a preclinical biotech with zero drugs and zero revenue. The prize? A DNA delivery platform that could unlock an entire generation of genetic medicines. It's Lilly's latest move in a $20 billion+ acquisition spree, and it says everything about where pharma is headed.
